Xenogenic cancer vaccines

Experimental Oncology

Volumn 32, Issue 2, 2010, Pages 61-65

  Potebnya, G P ^a   Symchych, T V ^a   Lisovenko, G S ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

Cancer; Cancer vaccines; Immunotherapy; Tumor associated antigens

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; AFLIBERCEPT; ANGIOPOIETIN RECEPTOR; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; CANCER VACCINE; ENDOGLIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; GELATINASE A; GLYCOPROTEIN GP 100; INTERLEUKIN 4; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; XENOGENIC CANCER VACCINE;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CANCER INHIBITION; CLINICAL TRIAL; COLORECTAL CANCER; CYTOKINE PRODUCTION; HUMAN; IMMUNOGENICITY; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NONHUMAN; PROSTATE CANCER; REVIEW; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; VACCINE PRODUCTION;

ANIMALS; ANTIGENS, HETEROPHILE; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; TRANSPLANTATION, HETEROLOGOUS;

EID: 77954600716     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. de Gruijl TD, van den Eertwegh AJ, Pinedo HM, et al. Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol Immunotherap 2008; 57: 1569-77.
2. Itoh K, Yamada A, Mine T, Noguchi M. Recent advances in cancer vaccines: an overview. Jpn J Clin Oncol 2009; 39: 73-80.
3. Andersen MH, Surensen RB, Schrama D, et al. Cancer treatment: the combination of vaccination with other therapies. Cancer Immunol Immunother 2008; 57: 1735-43.
4. Slingluff CLJr, Speiser DE. Progress and controversies in developing cancer vaccines. J Transl Med 2005; 3: 18-26.
5. Kochenderfer JN, Gress RE. A comparison and critical analysis of preclinical anticancer vaccination strategies. Exp Biol Med 2007; 232: 1130-41.
6. Srinivasan R, Wolchok JD. Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines. J Transl Med 2004; 2: 12.
7. Bergman PJ, Camps-Palau MA, McKnight JA, et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 2006; 24: 4582-5.
8. Scappaticci FA, Contreras A, Boswell CA, et al. Polyclonal antibodies to xenogeneic endothelial cells induce apoptosis and block support of tumor growth in mice. Vaccine 2003; 21: 2667-77. (Pubitemid 36561360)
9. Bowne WB, Srinivasan R, Wolchok JD, et al. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp 1999; 190: 1717-22.
10. Seledtsov VI, Felde MA, Samarin DM, et al. Immunological and clinical aspects of xenovaccinotherapy use for melanoma treatment. Rus Oncol Zh 2006; 4: 23-8 (In Russian).
11. Seledtsov VI, Niza NA, Felde MA, et al. Xenovaccinotherapy for colorectal cancer. Biomed Pharmacother 2007; 61: 125-30.
12. Alexander AN, Huelsmeyer MK, Mitzey A, et al. Develop ment of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma. Cancer Immunol Immunother 2006; 55: 433-42. (Pubitemid 43076895)
13. Tan G-H, Wei Y-Q, Tian L, et al. Active immunotherapy of tumors with a recombinant xenogeneic endoglin as a model antigen. Eur J Immunol 2004; 34: 2012-21.
14. Pupa SM, Iezzi M, Di Carlo E, et al. Inhibition of xenogeneic DNA vaccination. Cancer Res 2005; 65: 1071-8.
15. Hawkins WG, Gold JS, Blachere NE, et al. Xenogeneic DNA immunization in melanoma models for minimal residual disease. J Surg Res 2002; 102: 137-43.
16. Fong L, Brockstedt D, Benike C, et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 2001; 167: 7150-6. (Pubitemid 33144213)
17. Burgdorf SK, Fischer A, Claesson MH, et al. Vaccination with melanoma lysate-pulsed dendritic cells, of patients with advanced colorectal carcinoma: report from a phase I study. J Exp Clin Cancer Res 2006; 25: 201-6.
18. Yuan J, Ku GY, Gallardo HF, et al. Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun 2009; 9: 5.
19. Pupa SM, Iezzi M, Di Carlo E, et al. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Res 2005; 65: 1071-8.
20. Zhang W, Liu J, Wu Y, et al. Immunotherapy of hepatocellular carcinoma with a vaccine based on xenogeneic homologous a fetoprotein in mice. Biochem Biophys ResCommun 2008; 376: 10-4.
21. Su J-M, Wei Y-Q, Tian L, et al. Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2. Cancer Res 2003; 63: 600-7.
22. Yi T, Wei YQ, Tian L, et al. Humoral and cellular immunity induced by tumor cell vaccine based on the chicken xenogeneic homologous matrix metalloproteinase-2. Cancer Gene Ther 2007; 14: 158-64.
23. Okaji Y, Tsuno NH, Saito S. Vaccines targeting tumour angiogenesis - a novel strategy for cancer immunotherapy. EJSO 2006; 32: 363-70.
24. Pan J, Jin P, Yan J, Kabelitz D. Anti-angiogenic active immunotherapy: a new approach to cancer treatment. Cancer Immunol Immunother 2008; 57: 1105-14.
25. Li Y, Bohlen P, Hicklin DJ. Vaccination against angio-genesis- associated antigens: a novel cancer immunotherapy strategy. Curr Mol Med 2003; 3: 773-9. (Pubitemid 37536881)
26. Moskaleva EYu, Rodina AV, Gukasova NV, et al. Induction of melanoma-specific cellular immune response in mice after xenogenic vaccination with human melanoma cells injected in polyacrylamide gel implanted subcutaneously. Immunologiya 2006; 6: 329-36 (In Russian).
27. Chissov VI, Sergeeva NS, Severin SE, et al. The development of method of xenogenic anticancer vaccination of mice in preincapsulated polyacrylamide gel (mouse melanoma B-16 model). Molecular Med 2004; 2: 24-8 (In Russian).
28. Bergman PhJ, McKnight J, Novosad A, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: A phase I trial. Clin Cancer Res 2003; 9: 1284-90.
29. Liao JCF, Gregor P, Wolchok JD, et al. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun 2006; 6: 8-17. (Pubitemid 44030595)
30. Finocchiaro LM, Glikin GC. Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma. Gene Ther 2008; 15: 267-76.
31. Hawkins WG, Gold JS, Dyall R, et al. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery 2000; 128: 273-80. (Pubitemid 30622495)
32. Gritzapis AD, Mahaira LG, Perez SA, et al. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo. Cancer Res 2006; 66: 5452-60.
33. Ciesielski MJ, Apfel L, Barone TA, et al. Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas. Cancer Immunol Immunother 2006; 55: 1491-503. (Pubitemid 44327837)
34. Cho HI, Kim EK, Park SY, et al. Enhanced induction of anti-tumor immunity in human and mouse by dendritic cells pulsed with recombinant TAT fused human survivin protein. Cancer Lett 2007; 258: 189-98.
35. Charalambous A, Oks M, Nchinda G, et al. Dendritic cell targeting of survivin protein in a xenogeneic form elicits strong CD4+ T cell immunity to mouse surviving. J Immunol 2006; 177: 8410-21. (Pubitemid 44893803)
36. Gregor PD, Wolchok JD, Turaga V, et al. Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. Int J Cancer 2005; 116: 415-21. (Pubitemid 40993338)
37. Li M, Bharadwaj U, Zhang R, et al. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther 2008; 7: 286-96. (Pubitemid 351302523)
38. Palomba ML, Roberts WK, Dao T, et al. CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma. Clin Cancer Res 2005; 11: 370-9. (Pubitemid 40075817)
39. He QM, Wei YQ, Tian L, et al. Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. J Biol Chem 2003; 278: 21831-6.
40. Wei YQ. Immunotherapy of tumors with vaccines based on xenogeneic homologous molecules. Anti-Cancer Drugs 2002; 13: 229-35.
41. Lu Y, Wei YQ, Tian L, et al. Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor. J Immunol 2003; 170: 3162-70.
42. Xue SA, Stauss HJ. Enhancing immune responses for cancer therapy. Cell Mol Immunol 2007; 4: 173-84.
43. Luo Y, Wen YJ, Ding ZhY, et al. Immunotherapy of tumors with protein vaccine based on chicken homologous Tie-2. Clin Cancer Res 2006; 12: 1813-9.
44. Kamstock D, Elmslie R, Thamm D, Dow S. Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma. Cancer Immunol Immunother 2007; 56: 1299-309.
45. Wei YQ, Wang QR, Zhao X, et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 2000; 6: 1160-6.
46. Seledtsov VI, Shishkov AA, Surovtseva MA, et al. Xeno-vaccinotherapy for melanoma. Eur J Dermatol 2006; 16: 655-61.
47. Wolchok JD, Yuan J, Houghton AN, et al. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol Ther 2007; 15: 2044-50.